Patent · US Active

Immunobinders directed against TNF

US9803009B2 · kind B2 · utility

2Cited by

12References

12Claims

0Family size

Assignee

Abb Vie Inc. · US

Inventors

Chung-Ming Hsieh · Newton, US
Lorenzo Benatuil · Northborough, US
Yuliya Kutskova · Northborough, US
John E. Memmott · Framingham, US
Jennifer M. Perez · Worcester, US
Suju Zhong · Shrewsbury, US
Carrie Goodreau · Ludlow, US
Anca Clabbers · Rutland, US

Key dates

Filing date	Oct 24, 2012
Grant date	Oct 31, 2017
Priority date	—
Expiry date	Aug 30, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.